Literature DB >> 23588336

Human metapneumovirus (hMPV) infection in children with cancer.

Muhammad Ali1, Jillian M Baker, Susan E Richardson, Sheila Weitzman, Upton Allen, Oussama Abla.   

Abstract

Human metapneumovirus (hMPV) has recently emerged as an important cause of lower respiratory tract infections in hospitalized children, causing severe pneumonia and respiratory failure among immunocompromised patients. We retrospectively examined 30 children diagnosed with cancer whose nasopharyngeal swabs were positive for hMPV by direct fluorescent testing over a 5-year period. In 16/30 (53.3%) children, infection was confined to the upper respiratory tract, whereas lower respiratory tract infection occurred in 46.7%. The median duration of respiratory illness was 6.5 days with a hospital admission rate of 66.6%. No mechanical ventilation was required because of hMPV infection. Bronchoalveolar lavage tested positive for hMPV in 1 patient requiring prolonged inhaled steroid and bronchodilator therapy. All children recovered completely from hMPV infection. hMPV causes upper and lower respiratory tract infections in immunocompromised children. Infections may result in significant disease but is usually not fatal. In the absence of specific anti-viral drug, good symptomatic therapy appears to be the optimal therapy.

Entities:  

Mesh:

Year:  2013        PMID: 23588336     DOI: 10.1097/MPH.0b013e31828ac89c

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  3 in total

Review 1.  Modulation of Host Immunity by the Human Metapneumovirus.

Authors:  Pablo F Céspedes; Christian E Palavecino; Alexis M Kalergis; Susan M Bueno
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

2.  Burden of human metapneumovirus infections in patients with cancer: Risk factors and outcomes.

Authors:  Firas El Chaer; Dimpy P Shah; Joumana Kmeid; Ella J Ariza-Heredia; Chitra M Hosing; Victor E Mulanovich; Roy F Chemaly
Journal:  Cancer       Date:  2017-02-08       Impact factor: 6.860

Review 3.  HMPV in Immunocompromised Patients: Frequency and Severity in Pediatric Oncology Patients.

Authors:  Cesar Martinez-Rodriguez; Ma Del Rocio Banos-Lara
Journal:  Pathogens       Date:  2020-01-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.